Can AMD Be Reversed?
Dry AMD vs. Wet AMD: Why the Difference Matters
AMD comes in two forms, and they behave very differently. Understanding which type you have is the foundation for knowing what treatment can and cannot do for your vision.
Dry AMD is the more common form, accounting for the vast majority of all AMD diagnoses. It occurs when the light-sensitive cells in the macula, the central part of the retina responsible for sharp, detailed vision, gradually break down over time. The damage to these cells and the tissue beneath them is generally irreversible once it occurs. No current treatment can rebuild what has already been lost, though treatments exist to slow further decline.
Wet AMD is less common but tends to progress more rapidly. It occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, distorting and damaging the macula. Unlike dry AMD, wet AMD responds to treatment in ways that can actually improve vision in some patients, particularly when treatment begins promptly after diagnosis.
Geographic atrophy is the advanced stage of dry AMD. It describes areas of the macula where retinal cells have died, creating blind spots in central vision. This form of AMD now has its first approved treatments, which slow its progression, though they do not restore cells that have already been lost.
What Current Treatments Can and Cannot Do
Modern AMD treatment has advanced considerably, but it is important to understand where the line falls between slowing the disease and reversing it. Each treatment option available today targets a different part of the disease process.
Anti-VEGF (anti-vascular endothelial growth factor) injections are the primary treatment for wet AMD. A specialist injects medication directly into the eye to stop abnormal blood vessels from leaking and growing. Available medications include ranibizumab, aflibercept, bevacizumab, and faricimab, a newer dual-action drug that can be dosed as infrequently as every four months while delivering comparable results to earlier options.
In landmark clinical trials, a meaningful percentage of patients treated with anti-VEGF therapy gained significant vision, not just stabilization. Starting treatment quickly after diagnosis offers the best chance of this outcome. Delaying treatment reduces the likelihood of improvement and increases the risk of permanent vision loss.
Two medications, pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay), are now FDA-approved to treat geographic atrophy. They work by blocking a part of the immune system called the complement pathway, which drives the inflammatory damage behind geographic atrophy. These injections slow the rate at which atrophic lesions grow, which can meaningfully protect remaining vision over time.
It is important to understand that these medications do not restore vision or repair damage that has already occurred. Their benefit is in slowing the spread of the disease so that more retinal tissue is preserved.
In late 2024, the FDA cleared the Valeda Light Delivery System for intermediate dry AMD. This device uses specific wavelengths of light to support cellular function in the retina. Clinical data showed that treated patients experienced visual acuity improvements that were sustained over two years, making this the closest available option to functional vision improvement in dry AMD.
If you have intermediate dry AMD, ask your specialist whether this treatment may be appropriate for your situation.
The AREDS2 nutritional supplement formula, developed through National Eye Institute research, contains a specific combination of vitamins and minerals shown to reduce the risk of progression from intermediate to advanced AMD by approximately 25 percent over five years. These supplements do not reverse existing damage or restore lost vision. They are a proven tool for protecting the vision you still have if you are at intermediate or advanced-stage risk.
Emerging Therapies Aimed at Reversal
While no treatment available today fully reverses AMD damage, several approaches in clinical development are specifically designed to restore function rather than simply slow decline. These are not yet commercially available but represent real and meaningful progress.
Gene therapy aims to deliver long-lasting or permanent treatment through a single injection, rather than requiring ongoing visits. Researchers are developing gene therapies for both wet and dry AMD that would instruct retinal cells to produce protective proteins on their own. One therapy for wet AMD received FDA Fast Track designation in 2025, meaning regulators have recognized its potential and are working to facilitate its development. No gene therapy for AMD is commercially available yet, but the field is advancing steadily.
The retinal pigment epithelium, or RPE, is a layer of cells beneath the retina that supports the light-sensitive photoreceptors. AMD destroys RPE cells, and researchers are testing whether transplanting healthy RPE cells derived from stem cells can replace what is lost. Early-phase clinical trials have demonstrated that this approach is feasible, with transplanted cells surviving and integrating in some patients.
This research is still in early stages, and no stem cell treatment for AMD is approved or commercially available. Patients should be cautious of clinics offering unregulated stem cell therapies, as these carry serious risks including further vision loss.
Mitochondria are the energy-producing structures inside cells, and their decline in retinal cells is believed to play a significant role in AMD progression. Investigational drugs including risuteganib and elamipretide target this energy deficit directly. Early clinical trials have shown potential to improve vision in some patients with intermediate dry AMD, which would make them among the first treatments to show any restorative effect in dry AMD.
These medications are not yet FDA-approved, but they represent a genuinely new direction in AMD research that may eventually offer restoration rather than just protection.
Steps You Can Take Right Now
While research continues, there is a great deal you can do today to protect the vision you have and stay positioned to benefit from emerging therapies.
If you have wet AMD or notice sudden changes in your central vision, such as new distortion, a blind spot, or lines appearing wavy, contact your eye care provider right away. Wet AMD can cause rapid damage, and every day of delay can affect how much vision can be saved or improved. Anti-VEGF treatment works best when started early, and the window for the best outcomes can be narrow.
If you have intermediate dry AMD, a combination of lifestyle strategies can meaningfully slow progression. Your specialist may recommend AREDS2 supplements, quitting smoking, following a Mediterranean-style diet rich in leafy greens and fish, and staying physically active. For those with geographic atrophy, complement inhibitor injections offer an additional layer of protection.
- Take AREDS2 supplements as directed by your eye care provider
- Quit smoking, which is one of the strongest known risk factors for AMD progression
- Eat a diet high in dark leafy greens, colorful vegetables, and omega-3-rich fish
- Exercise regularly to support overall vascular and retinal health
- Monitor your central vision regularly using an Amsler grid
The AMD treatment landscape is changing faster than at any previous point in history. Staying in regular follow-up with your specialist ensures that you will be informed about clinical trials and new approvals as they occur. Eligibility for emerging therapies often requires specific disease stage and history, and maintaining a current relationship with your care team keeps those doors open.
Frequently Asked Questions
These questions address the practical decisions patients most often face when navigating AMD treatment and what to expect going forward.
Stopping injections without your specialist's guidance carries a real risk of reactivation. Wet AMD is a chronic condition, and the abnormal blood vessels that caused the initial damage often regrow when treatment is paused. Your specialist may be able to extend the time between injections as your condition stabilizes, particularly with newer medications like faricimab, but the decision to reduce or stop treatment should always be made together with your care team based on close monitoring.
Yes, in most cases. For wet AMD, even patients with existing vision loss can benefit from anti-VEGF treatment because additional leakage and damage can still occur without intervention. For dry AMD, slowing further progression preserves the functional vision that remains. The goal shifts based on your stage, but there is almost always a meaningful reason to pursue treatment rather than watch and wait.
No approved stem cell treatment for AMD exists as of 2026. Clinics advertising stem cell therapies for AMD outside of formal clinical trials are offering unproven and potentially dangerous procedures. Reports of severe vision loss and other complications from unregulated stem cell injections have been documented. If you are interested in stem cell research, ask your specialist about legitimate clinical trials, which can be searched through the national clinical trials registry.
Eligibility for AMD clinical trials depends on your AMD type, the stage of your disease, your treatment history, and other health factors. The best first step is to bring it up at your next appointment with your specialist, who can advise you based on your specific profile. You can also search open studies independently through the national clinical trials registry. Staying in regular follow-up is the most reliable way to learn about trials as they open and remain a candidate.
Diet is one supportive factor among several, not a standalone treatment. A Mediterranean-style diet rich in leafy greens, colorful vegetables, and omega-3 fatty acids is associated with reduced inflammation and better retinal health, and it complements AREDS2 supplements well. However, diet cannot substitute for medical treatment, particularly in wet AMD or geographic atrophy, where approved therapies provide measurable clinical benefit that diet alone cannot replicate.
Your specialist is best positioned to advise you based on your current disease stage. In general, AREDS2 supplements are recommended for people with intermediate AMD or advanced AMD in one eye to reduce the risk of further progression. Even when reversal is not possible, slowing progression can preserve meaningful functional vision, and the supplements buy time for additional treatment options to become available. Continue taking them as long as your specialist recommends.
Our Commitment to Your Vision
AMD care is one of our areas of deep focus, and our team stays at the forefront of both established treatments and emerging options so that every patient receives the most current, evidence-based care available. Whether you are newly diagnosed or managing AMD that has progressed, we are here to help you protect what you have and stay positioned for what is coming. We welcome you to schedule a visit with us and take the next step toward informed, proactive eye care.
I take my mother here monthly the staff is amazing, always welcoming and attentive. Keep up the wonderful job.
Scully Sully
Siempre es un placer ver al Dr. Fernandes. El doctor y el personal son muy profesionales, amables y comprensivos.
Christina
I’ve been seeing the doctor for years and love him. He listens carefully, explains thoroughly, and the staff is incredibly helpful. Other practitioners should use this office as a model.
Uncle Bertie
This place is great the doctor really takes his time with patients. He explains treatments and procedures well, staff are friendly, and they even offer a breakfast bar for everyone.
SLK Production
The practice is impeccable. Drs medical skills gave me extra years of vision when I had no hope. Staff are professional and kind.
Vantura Henderson